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Abstract
Background: Globally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or
rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor
treatment adherence. This study aims to assess the respective contributions of the different causal pathways
leading to MDR/RR-TB at re-treatment.
Methods: We use a simple mathematical model to simulate progression between the different stages of disease
and treatment for patients diagnosed with TB. The model is parameterised using region and country-specific TB
disease burden data reported by the World Health Organization (WHO). The contributions of four separate causal
pathways to MDR/RR-TB among re-treatment cases are estimated: I) initial drug-susceptible TB with resistance
amplification during treatment; II) initial MDR/RR-TB inappropriately treated as drug-susceptible TB; III) MDR/RR-TB
relapse despite appropriate treatment; and IV) re-infection with MDR/RR-TB.
Results: At the global level, Pathways I, II, III and IV contribute 38% (28–49, 95% Simulation Interval), 44% (36–52,
95% SI), 6% (5–7, 95% SI) and 12% (7–19, 95% SI) respectively to the burden of MDR/RR-TB among re–treatment
cases. Pathway II is dominant in the Western Pacific (74%; 67–80 95% SI), Eastern Mediterranean (68%; 60–74 95% SI)
and European (53%; 48–59 95% SI) regions, while Pathway I makes the greatest contribution in the American (53%;
40–66 95% SI), African (43%; 28–61 95% SI) and South-East Asian (50%; 40–59 95% SI) regions.
Conclusions: Globally, failure to diagnose MDR/RR-TB at first presentation is the leading cause of the high proportion
of MDR/RR-TB among re-treatment cases. These findings highlight the need for contextualised solutions to limit the
impact and spread of MDR/RR-TB.
Keywords: Tuberculosis, Multidrug-resistant tuberculosis, Re-treatment, Causal pathway, Misdiagnosis, Inappropriate
therapy, Drug resistance amplification
Background
Multidrug-resistant tuberculosis (MDR-TB), defined as
resistance to at least rifampicin and isoniazid, is a major
threat to global tuberculosis (TB) control [1]. The World
Health Organization (WHO) estimates that 3.9% of all
new TB cases had MDR-TB or rifampicin-resistant TB
(RR-TB) in 2015 [2]; in comparison to 21% of TB patients
with a history of prior treatment. The dramatic gap be-
tween these two estimates can be explained by the potential
for a TB patient to acquire drug resistance during treat-
ment, particularly if there is treatment interruption or de-
fault [3–7]. However, in addition to acquired (secondary)
drug resistance resulting from poor treatment adherence,
multiple other factors may contribute to the higher rate of
MDR/RR-TB observed among re-treatment cases.
The potential for primary transmission of drug-resistant
TB has long been under-recognised [8]. A large MDR-TB
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outbreak in New York City [9], and a cluster of extensively
drug-resistant (XDR) TB cases in South Africa provided
stark evidence that some drug-resistant strains are highly
transmissible [10]. Epidemic spread of MDR-TB has since
been confirmed in multiple settings [11], and molecular
methods have demonstrated the importance of re-
infection to TB recurrence, especially in endemic areas
[12]. Among clinical MDR-TB strains, the fitness cost
associated with acquired drug resistance can be overcome
by various compensatory mechanisms [13], and the oppor-
tunity for compensatory evolution is enhanced by selective
pressure from poorly targeted treatment [14].
Although the End TB strategy calls for universal access
to drug susceptibility testing (DST) [15], new TB cases
remain infrequently tested for drug resistance globally.
Therefore, newly presenting MDR/RR-TB patients will
often receive the same regimen as drug-susceptible TB
(DS-TB) cases. However, although some clinical response is
possible, cure rates resulting from standard first-line treat-
ment are low even with adequate treatment adherence and
these patients mostly re-present as failure or relapse cases
[16]. Given the high rate of drug resistance among re-
treatment cases, they are usually prioritised for pheno-
typic DST or genotypic testing with Xpert MTB/RIF®,
which introduces a strong case detection bias. Therefore,
re-treatment cases with MDR/RR-TB represent a mixed
bag, including secondary acquired and primary transmitted
MDR/RR-TB. The contribution of these subgroups to the
total burden of MDR/RR-TB among re-treatment cases
has been poorly quantified and may be highly setting-
dependent. A recent modelling study suggested that the
emergence of MDR-TB is mostly driven by transmission
of such strains [17], but the contribution of different
causal pathways to MDR/RR-TB at re-treatment and a
detailed geographic breakdown of their contribution
have never been conducted. Better quantification of the
contributing pathways (causes) would therefore provide
insight into the evolution of the global MDR/RR-TB
epidemic and guide region-specific programmatic ap-
proaches to its control.
We present a simple probability tree model, using
regional disease estimates, to quantify the proportions
of MDR/RR-TB at re-treatment attributed to four principle
causal pathways: I) initial drug-susceptible TB with resist-
ance amplification during treatment; II) initial MDR/RR-TB
inappropriately treated as drug-susceptible TB; III) MDR/
RR-TB relapse despite appropriate treatment; and IV)
re-infection with MDR/RR-TB.
Methods
Study design
We developed a model to quantify the contribution of
different causal pathways towards the high burden of
MDR/RR-TB observed among re-treatment cases in
2015. Patients were not involved in this study as only
data from the WHO and from published literature were
used. Model parameters include key characteristics of
the different WHO regions, TB burden estimates and
reported data from National TB control programs for
2013. All seven WHO regions were considered: Africa
(AFR), the Americas (AMR), Europe (EUR), South East Asia
(SEAR), the Eastern Mediterranean (EMR) and Western
Pacific (WPR) regions, as well as combined Global estimates
(GLOBAL). Since the model is intended for moderate to
high burden countries only, where TB transmission
remains poorly controlled, a country-specific analysis
was performed on the 104 countries with an estimated
TB-incidence ≥50 new cases/100,000/year in 2013.
Model principle
A simple probability tree model was used to simulate
progression between the different stages of infection,
disease and treatment for patients diagnosed with TB
(Fig. 1). The use of two distinct pathways based on initial
susceptibility of primary TB infection allowed consider-
ation of parameters that are specific to DS-TB and
MDR/RR-TB. For simplicity, individuals presenting with
mono-resistant or poly-resistant TB without rifampicin
resistance were considered to be DS-TB, while resistance
beyond MDR/RR-TB was considered to be MDR/RR-TB.
The model considered that new MDR/RR-TB cases
were treated appropriately only if they were diagnosed
as MDR/RR-TB cases and started on a second-line regi-
men. Accordingly, the probability that a new MDR/RR-TB
case is treated appropriately is obtained by multiplying the
DST coverage (b) by the proportion of notified MDR/RR-
TB cases that start on second line regimen (h). Any treat-
ment regimen could result in cure, failure (unsuccessful
treatment) or death. Individuals lost to follow-up are
assumed to experience failure in the baseline analysis
but alternate scenarios were considered in a sensitivity
analysis. Cured individuals are assumed to have cleared
infection and could only be affected by a new episode
of TB in case of reinfection.
Only DS-TB patients could develop drug resistance
amplification to become an MDR/RR-TB case. Since the
treatment success rate for new DS-TB cases (c) is not
reported by the WHO, we used the reported treatment suc-
cess rate in all new TB cases as an estimate for c. This is
consistent with the observations that that although undiag-
nosed MDR/RR-TB cases (which represent a small propor-
tion of the new cases) are less likely to achieve a favorable
treatment outcome, this is counterbalanced by the observa-
tion that many patients classified as TB treatment success
were not bacteriologically confirmed, which may overesti-
mate treatment success.
Re-infection was considered possible once patients had
completed treatment, with the proportion estimated from
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the local TB incidence using the regression equation
proposed by Wang and colleagues [18]. That is, param-
eter g presented in Fig. 1 was indirectly estimated from
the local TB-incidence and the other model parameters
(see Additional file 1). We assumed that the proportion
of MDR/RR-TB among re-infection cases was the same
as that for new TB cases. Most model parameters (TB-
incidence, a, b, c, d, h, m and k) were estimated from
the Global TB Report 2016 reporting of local-level data
and estimates for the year 2015, while the remaining
two parameters (e and f ) were estimated from the
literature [2, 8, 19–23] (see Additional file 1 for details).
Table 1 presents the definitions of the different parame-
ters along with the values used for each of the WHO
regions.
Stochastic method for generating parameter values
For the analysis by WHO region, some parameter values
were associated with an uncertainty interval (Table 1). In
an earlier version of this work, we also estimated uncer-
tainty for the other parameters by using the cohort sizes
reported by WHO. However, given that the cohort sizes
were extremely large, the associated uncertainty intervals
were very narrow, making the analysis with point esti-
mates equivalent to that including uncertainty ranges.
Therefore, we used point estimates for these parameters
in the main analysis and considered broader uncertainty
ranges in a supplementary analysis (see Additional file 1).
We used a stochastic Monte-Carlo method to inde-
pendently generate a large number of parameter sets
(1,000,000). For each run and for each parameter associated
with an uncertainty interval, values were independently
drawn using beta distributions with shape parameters α = 2
and β = 2, scaled and transposed in order to cover the
corresponding uncertainty interval. In contrast, country-
specific analysis was performed using the point estimates
presented in Additional file 1: Table S2.
Similar to the region-specific analysis, parameters (TB-
incidence, a, b, c, d, h and m) were estimated locally in
the country-specific analysis and estimates were ex-
tracted from the tuberculosis country profiles available
from WHO [24]. Where a country-specific estimate was
not available and for the risk of death in MDR/RR-TB
patients (k), we used the value of the WHO region to
Fig. 1 Presentation of the model structure and parameters. Parameters correspond to the probability of a patient transitioning to the state at the end of
the corresponding arrow if initially in the state at the start of this arrow. The coloured boxes correspond to the outputs that we observe for quantifying the
respective contributions of the different pathways to MDR/RR-TB at re-treatment. *‘new TB case’ stands for a patient presenting primary TB disease and
who undergoes therapy against TB. Parameter a is the rate of MDR/RR-TB among new TB-cases. Parameter b is the DST coverage in new TB-cases while
parameter h stands for the proportion of notified MDR/RR-TB cases that start on second-line regimen. Parameters c and d are the treatment success rates
for new DS-TB cases and new MDR/RR-TB cases respectively. Parameter e represents the treatment success rate for MDR/RR-TB treated with first-line
regimen. Parameter f is the risk of drug-resistance amplification for a DS-TB patient failing therapy. Parameter g is the proportion of recovered individual
who get re-infected with TB. Parameters m and k are the death rate during treatment for DS-TB and MDR/RR-TB patients respectively
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which the country belongs. If three or more estimates
were not accessible for one country or if the country’s
incidence rate was <50 per 100,000 per year, the results
of the analysis were excluded. This disease burden limi-
tation was applied, since the epidemiology in low burden
settings mostly represents imported disease and not
local transmission. Therefore, we do not consider the
model to be applicable to such settings.
Observed outputs
For each geographical area, we estimated the contribu-
tions of the four different causal pathways to MDR/RR-
TB at re-treatment: I) initial drug-susceptible TB with
resistance amplification during treatment; II) initial
MDR/RR-TB inappropriately treated as drug-susceptible
TB; III) MDR/RR-TB relapse despite appropriate treat-
ment and IV) re-infection with MDR/RR-TB. In the con-
text of this study, drug resistance amplification is
defined as acquisition of rifampicin resitance druing pri-
mary treatment. Each of these contributions was calcu-
lated by dividing the proportion of TB cases that arrive
in each associated category by the total burden of MDR/
RR-TB at re-treatment.
For each of the WHO regions, we observed a fifth out-
put to assess the reliability of the model; the absolute
proportion of MDR/RR-TB among re-treatment cases.
We verified our model outputs against real world WHO
report estimates for each of the different regions.
Sensitivity analyses
Our analysis of the results on the seven WHO regions took
into account uncertainty in the estimates of the parameters
c, e and f, which were not directly available in the Global
TB Report 2016. Thus, we observed how model outputs
were impacted when treatment success rates for DS-TB (c)
varied between 70 and 95%; probability of treatment
success for MDR/RR-TB cases treated as DS-TB cases (e)
varied between 0 and 20%; and risk of drug resistance amp-
lification when failing first-line treatment for DS-TB (f) var-
ied between 0 and 26%.
In our baseline analysis, we assumed that all MDR/
RR-TB patients have the same risk of death (k), regard-
less the type of therapy received. A sensitivity analysis
was performed to test this assumption by considering a
modified mortality for MDR/RR-TB patients treated in-
appropriately. An additional sensitivity analysis was con-
ducted to test the assumption concerning the proportion
of MDR/RR-TB among re-infection cases, which was
considered to be the same as for new TB cases in the
baseline analysis.
Finally, in another sensitivity analysis we considered dif-
ferent scenarios concerning the treatment outcomes for
individuals who were lost to follow-up or not evaluated.
Results
Figure 2 shows the proportions of MDR/RR-TB at re-
treatment obtained from the model when applied to the
seven WHO regions, compared to corresponding estimates
provided by the WHO TB report 2016. We observed
closely matching rates of MDR/RR-TB for every region.
Figure 3 quantifies the contributions of the different
causal pathways of MDR/RR-TB at re-treatment in each
of the seven WHO regions. At the global level, the
model suggests that the greatest number of MDR/RR-TB
cases identified at re-treatment result from initial MDR/
RR-TB that was inappropriately treated as DS-TB (44%,
36–52, 95% simulation interval). This was a leading
pathway in every WHO region, with rates ranging from
35% (28–42) in South-East Asia to 74% (67–80) in the
Western Pacific region. MDR/RR-TB at re-treatment
resulting from drug resistance amplification represented
38% (28–49) of the total burden globally. Drug resistance
amplification was estimated to be the leading pathway to
MDR/RR-TB at re-treatment in the American, South-East
Asian and African regions; accounting for 53% (40–66),
50% (40–59) and 43% (28–61) of the total burden respect-
ively. Elsewhere, the contribution of drug resistance amplifi-
cation during primary treatment ranged from 17% (11–25)
(Western Pacific) to 24% (Eastern Mediterranean).
Model outputs suggested that failure of appropriate
second-line regimens against MDR/RR-TB contributes
Fig. 2 Rates of MDR/RR-TB at re-treatment by WHO region. Blue
crosses show the estimates presented in the WHO Global Tuberculosis
Report 2015 and vertical blue bars represent the associated 95%
confidence intervals. Orange dots show the average model outputs
while vertical orange bars represent the 95% central ranges obtained
from the uncertainty analysis. WHO regions are designated as following:
African region (AFR), American region (AMR), Eastern Mediterranean
region (EMR), European region (EUR), South East Asian region (SEAR),
Western Pacific region (WPR) and Global region (GLOBAL)
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little to the total burden of MDR/RR-TB at re-treatment
(6% globally). The highest contribution from this path-
way was found in Europe, with 18% (16–20) of the total
burden of MDR/RR-TB at re-treatment. The role of re-
infection was also low across all WHO regions, with an
estimated global contribution of 12% (7–19); regional
estimates varied from 3% (2–6) in America to 16% (8–
27) in Africa.
Sensitivity analysis noted no sensitivity to parameter e
(treatment success rate in MDR/RR-TB patients treated
as DS-TB cases), whereas a lower treatment success rate
for DS-TB (c) or a higher risk of drug resistance amplifica-
tion (f) led to similar impacts on the results. Specifically,
the main contributors to MDR/RR-TB at re-treatment
would remain failure to provide appropriate anti-TB treat-
ments and drug resistance amplification during treatment
in all settings, although the respective contributions of
these two pathways would be modified. The contribution of
drug resistance amplification would increase, while the con-
tribution of inappropriate diagnosis and treatment would
decrease.
Our analyses including broader uncertainty ranges led
to very similar results compared to the baseline analysis
(see Additional file 1). The additional explorations testing
our assumptions regarding both the mortality of MDR/
RR-TB cases and the rate of MDR/RR-TB at re-infection
demonstrate that our baseline assumptions represented at
most a minimal source of bias. Finally, our analysis con-
cerning the treatment outcomes in individuals who were
lost to follow-up or not evaluated revealed that the contri-
bution of pathway II (initial MDR/RR-TB inappropriately
treated) would become more important in all WHO
region if more of the unknown treatment outcomes were
actually success. Detailed results of the different sensitivity
analyses are presented in the Additional file 1.
Figure 4 presents the leading cause of MDR/RR-TB
among re-treatment cases in the 105 countries with a
TB-incidence ≥50 new cases/100,000/year and sufficient
data for analysis. The quantitative results regarding the
Fig. 3 Contributions of the different causal pathways leading to
MDR/RR-TB at re-treatment in the seven WHO regions. Results are
expressed as percentages of the total burden of MDR/RR-TB at
re-treatment. For each region, the mean values and the intervals
containing 95% of the values obtained from simulation of
1,000,000 sets of parameters are presented by the bars and the
lines respectively. WHO regions are designated as following: African
region (AFR), American region (AMR), Eastern Mediterranean region
(EMR), European region (EUR), South East Asian region (SEAR), Western
Pacific region (WPR) and Global region (GLOBAL)
Fig. 4 Representation of the leading pathway to MDR/RR-TB at re-treatment around the world. Only countries with TB-incidence ≥50 new cases/
100,000/year and for which sufficient data was available (see the Methods section for a full description) are represented
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contribution of each of the different pathways are avail-
able in the Additional file 1. At the country-level, the
leading contributor to drug resistance at re-treatment
showed marked geographic variation, broadly similar to
those observed in the regional analysis, but with interest-
ing local findings. In the African region, while drug re-
sistance amplification during primary treatment was
found to be dominant in the northern part of the region,
inappropriate treatment of primary MDR/RR-TB was
the leading causal pathway to MDR/RR-TB at re-
treatment in the countries of the Southern part of
Western Africa (from Guinea Bissau to Cameroon). In
the rest of the African region, we observed a relatively
even division between the two main pathways leading to
MDR/RR-TB at re-treatment (inappropriate therapy and
drug resistance amplification). Re-infection with an
MDR/RR-TB strain was the leading pathway in only one
country, Lesotho, contributing 37% of cases. This cause
was also common in Swaziland where it accounted for
34% of MDR/RR-TB at re-treatment. Failure of second-
line regimens was the leading pathway to MDR/RR-TB
at re-treatment in three countries: Lithuania (50%),
Georgia (33%) and Peru (31%). In South Africa, 36% of
cases were due to drug resistance amplification, while
inappropriate treatment of primary MDR/RR-TB and
re-infection with MDR/RR-TB contributed 23 and
33% respectively to the total burden of MDR/RR-TB
at re-treatment.
Discussion
This study is the first to use a probabilistic mathematical
model to explore the different causal pathways leading
to MDR/RR-TB at re-treatment and to quantify their re-
spective contributions. By using regional and country-
specific inputs, the resulting model incorporated local
variations in TB control activity and disease burden.
Despite these local variations, broad regional trends
were observed. Most importantly, and contrary to previ-
ous dogma that emphasised the central role of drug re-
sistance acquisition, undetected MDR/RR-TB at initial
diagnosis was the most important reason for the high
rates of MDR/RR-TB found among re-treatment cases in
most regions. Moreover, this finding was obtained under
the conservative assumption that all individuals who
were lost to follow-up or not evaluated experienced
treatment failure, and our sensitivity analysis demon-
strates that the contribution of undetected MDR/RR-TB
would increase further if some of these unknown out-
comes were favourable.
Our findings therefore indicate that drug resistance
amplification due to poor first-line treatment adherence
is not the predominant pathway to MDR/RR-TB at re-
treatment. Instead, the greatest number of MDR/RR-TB
cases result from transmission of MDR/RR-TB strains
and it is the lack of appropriate MDR/RR-TB identifica-
tion at initial presentation that underlies the high rates
of MDR/RR-TB at re-presentation. These observations
emphasize the importance of universal MDR/RR-TB
screening followed by rapid initiation of appropriate
treatment. They therefore highlight the potential impact
that novel rapid diagnostic tests that include rifampicin
sensitivity testing such as Xpert MTB/RIF® could have
on the MDR-TB epidemic. Our findings concur with the
outcomes of recent studies demonstrating that primary
transmission contributes more substantially to the
MDR/RR-TB burden than drug resistance acquisition or
amplification during treatment [17, 25]. Interestingly,
the model also suggests that failure of second-line regi-
mens may make a significant contribution to the burden
of MDR/RR-TB at re-treatment, especially in settings
such as Eastern Europe where MDR vigilance is high
and patients are able to access MDR/RR-TB treatment.
Our analysis has crucial implications for TB control as it
highlights regional variation regarding the causes of
MDR/RR-TB at re-treatment, indicating that targeted
programmatic strategies may be more effective than
elaborating a single global plan. In all regions and par-
ticularly in the Western Pacific and the Eastern Mediter-
ranean, , the introduction of universal drug resistance
screening of newly diagnosed TB cases seems critical.
Universal drug resistance screening would reduce the
burden of MDR/RR-TB at re-treatment and limit on-
going MDR/RR-TB transmission within the community,
as well as directly benefiting patients who would other-
wise have been inappropriately managed with first-line
treatment during their initial disease episode.
Access to appropriate therapy is crucial as DS-TB
cases that are not properly treated may experience drug
resistance amplification. In the Americas, South-East
Asia and Africa, the greatest contribution of MDR/RR-
TB identified at re-treatment resulted from drug resist-
ance amplification during first-line treatment of DS-TB.
Amplification is driven by high treatment failure rates
on first-line therapy, which indicates that improved
treatment adherence should be a major public health
priority in these settings. The DOTS strategy has dem-
onstrated ability to improve treatment outcomes and
therefore, meticulous scale-up should reduce the MDR/
RR-TB burden in these regions [26–29]. This requires
strong political commitment together with substantial
and sustainable financing, especially in low and middle
income countries.
Re-infection with MDR/RR-TB was found to play an
important role in Lesotho, Swaziland and South Africa,
which were the only countries where it contributed
more than one third to the total burden of MDR/RR-TB
at re-treatment. This may be explained by the excep-
tional infection pressure that exists in such settings with
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a TB-incidence ranging between 565 and 834 cases/
100,000 people in 2015 [2]. Accordingly, in settings with
very high infection pressure, as occur in particular
disease “hot-spots”, a more comprehensive response is
required to limit TB transmission and case numbers of
both DS-TB and MDR/RR-TB. In these three countries
of Southern Africa, such an approach would include
better control of the severe HIV epidemic, enhanced
active case finding strategies, and creative interventions
to reduce TB transmission within communities [30]. In
South Africa, transmission of MDR/RR-TB caused around
64% of MDR/RR -TB cases diagnosed at re-treatment,
which is supported by molecular epidemiology studies in-
dicating substantial clonal spread of multiple MDR-TB
strains [11]. In addition to a strong emphasis on improved
treatment adherence, consideration should be given to
additional efforts that may reduce TB transmission within
disease “hot spots” [31, 32].
Despite the relative simplicity of our model, uncer-
tainty analysis demonstrated robust conclusions across
plausible parameter ranges. We are also reassured by the
comparison between model outputs and independently
calculated WHO estimates of the total rate of MDR/RR-
TB at re-treatment, which demonstrates very close ap-
proximation at both the global and region-specific level.
Moreover, the model was most sensitive to variation in
parameters for which programmatic (treatment success
rate in new DS-TB cases, c) or evidence-based (risk of
drug resistance amplification during treatment, f ) data
were available and of reasonable quality, whereas it was
insensitive to variation in the most uncertain parameter
(treatment success rate for MDR/RR -TB treated as DS-
TB, e). In particular, the sensitivity analyses demon-
strated that a lower treatment success rate for DS-TB
and a higher risk of drug resistance amplification would
both contribute to a higher contribution of drug resist-
ance amplification to the burden of MDR/RR-TB at re-
treatment.
Model limitations include the fact that only two phe-
notypes of TB were considered, DS and MDR/RR-TB.
Other profiles such as mono- or poly-resistant, or add-
itional resistance beyond MDR-TB were reclassified into
these two categories, since the available WHO data do
not provide additional sub-classification. Further investi-
gations could be conducted in settings where more de-
tailed drug resistance profile data are available. However,
our sensitivity analyses indicate that our general conclu-
sions are maintained in settings with high prevalence of
mono- or poly-resistant TB. In such settings, treatment
success rates for these strains are expected to be lower,
while the risk of drug resistance amplification leading to
MDR/RR-TB would increase. Our sensitivity analyses in-
dicate that in these settings, the contribution of drug re-
sistance amplification during primary treatment would
increase, while the contribution of inappropriate diagno-
sis and treatment would diminish. Another limitation is
linked to the uncertainty around some parameter esti-
mates, in particular those that were not directly available
from the WHO. As discussed above, although our results
were sensitive to some model parameters, we do not believe
this would jeopardise our general findings. Our model does
not take into account nosocomial transmission of MDR/
RR-TB. While we acknowledge this as a possible cause of
MDR/RR-TB presentation at re-treatment [33, 34], insuffi-
cient data were available to inform its isolated contribution
at the local level. Nevertheless, we can anticipate that our
model may underestimate the contribution of reinfection in
settings where nosocomial transmission of MDR/RR-TB is
significant. Future works could investigate this issue more
specifically and distinguish the contribution of nosocomial
transmission from that of general reinfection with MDR/
RR-TB strains.
The resolution of our analysis was restricted to the
national level and we were unable to consider sub-
national heterogeneity. Moreover, our regional-level
estimates were based on common analyses of aggre-
gate data due to missing country-level data and as
countries were excluded from the analysis if TB inci-
dence was <50 cases/100,000/year. This may not lead
to the same estimates as aggregating the results of
separate analyses of the different countries as the
model that we use is non-linear. National TB pro-
grams need to consider particular settings within the
country, since transmission dynamics may be altered
within “hot-spot” areas, while cultural issues and spe-
cific service delivery challenges also require consider-
ation [35, 36]. In future, our model could be adapted
to guide local policies, for example through an online
tool usable by policy makers who could input parame-
ters from local programmatic data. Such a tool could
be modified in real-time as new data become available
to improve and update parameter estimates. Indeed it
is important to note that our estimates correspond to
the situation in 2015 and that the fractions attribut-
able to each pathway are likely to vary over time.
Conclusions
Our findings highlight the need for contextualised so-
lutions to limit the impact and spread of MDR/RR-TB.
Although more effective MDR/RR-TB treatment is a
universal need and certain common factors should be
addressed, a better understanding of the local causal
pathways could assist better targeted public health re-
sponses. Importantly, our findings suggest that simply
“turning off the tap” through improved programmatic
management of drug-susceptible TB will be insuffi-
cient to contain the spread of drug-resistant TB.
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